Projects & Initiatives
One of the most exciting and beneficial elements of WECAN is the potential for true collaboration across the European cancer community.
WECAN provides a platform for coordination and collaboration. We enable long-term benefits for the cancer patient community and stakeholders through shared goals, learning, and development.
Ongoing projects & Initatives
European Atlas on Clinical Trials in Cancer and Hematology
EuroACT is a research project initiated by WECAN and the European Hematology Community to understand the clinical trial landscape in WHO European Region.
Reasonable agreements between patient advocates and pharmaceutical industry
Collaboration with 35 patient organisations, 16 pharmaceutical companies and 7 other project partners to make the legal relationship between patient advocates and pharmaceutical companies easier and more acceptable
Setting International Standards in the Analysis Quality of Life data
WECAN, represented by Myeloma Patient Europe (MPE), ensures that the patient’s perspective is taken into account in the recommendations, and that a lay version of the recommendations will be available for the wider public.
Global Principles for remunerating the patient community for interactions with the pharmaceutical industry
PFMD and contributors are driving a comprehensive co-creation effort to establish a trusted process to remunerate the patient community. WECAN, represented by Myeloma Patient Europe (MPE), ensures that the patient’s perspective is taken into account.
COVID-19
The COVID-19 epidemic is of concern to many cancer patients. Many of the European cancer patient organisations are providing information about COVID-19 and specific recommendations to their patient community. See the
Past Projects
Survey on Fair Market Value
Compensation for the work of patient advocates at Fair Market Value
Results of the WECAN Survey on Fair Market Value
(6 March 2019)
EU integration of Health Technology Assessment
WECAN position on further EU integration of Health Technology Assessment (HTA)